The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2020 | How to define high risk smoldering myeloma
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses how to distinguish high-risk smoldering myeloma patients. Currently, clinical factors can be investigated to identify high-risk patients, for example, tumor burden, light chain ratio and monoclonal protein. However, there is a need for a more precise measurement beyond a single time recording. For example, dynamic clinical evolution such as a decrease in hemoglobin and an increase in M-spike light chains. The use of genomics could further increase precision. Research indicates that investigating 3 genomic factors improves prediction. In the future, the role of the microenvironment should be investigated for increased prediction precision. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
